Zydus Lifesciences Ltd receives final USFDA approval to market generic Theophylline extended-release tablets of strengths 300 mg and 450 mg for asthma and COPD treatment. The drug will be manufactured at the group's formulation manufacturing facility in Ahmedabad SEZ, India, with annual sales of USD 12.6 million citing IQVIA MAT March 2024 data.
Disclaimer : Mymoneytimes implements extreme caution and care in collecting data before publication. Mymoneytimes does not liable for the adequacy, accuracy or completeness of any given information. Hence we are not liable for any kind of direct or indirect loss caused by the use of such information.